Prospective analysis of seizures occurring in human immunodeficiency virus type-1 infection.

J NeuroAIDS 1996 ;1(4):59-69

, Level 2, 376 Victoria Street, Syndey NSW, 2010, Australia.

A prospective, case-control study was undertaken to characterise seizures occurring in the context of human immunodeficiency type-1 (HIV-1) infection. Fifty consecutive patients with a documented seizure were enrolled along with fifty control patients. Among cases the median CD4 cell count was 8/mm3 and 84% had a prior AIDS defining illness; 14/mm3 and 80% among the control group. Generalised seizures were seen in 84%, partial with secondary generalisation in 10% and partial in 6%. Associated conditions included cerebral toxoplasmosis (22%), cryptococcal meningitis (8%), progressive multifocal leukoencephalopathy (6%), cytomegalovirus encephalitis (6%), central nervous system (CNS) lymphoma (2%), and other causes (14%) including pre-HIV epilepsy. No associated condition was identified in 42% of patients of whom 18% were receiving foscarnet therapy at the time of seizure, compared with 4% of control patients (p < 0.001). Concentrations of cerebrospinal fluid â2-microglobulin and neopterin, markers that have been associated with HIV-1 involvement of the CNS, were elevated in 12/12 and 13/13 patients, respectively, of the group with no identifiable cause for their seizure. We conclude that seizures occur principally in patients with advanced HIV-1 disease, with opportunistic infections of the CNS the predominant underlying condition. In the group with no identifiable cause foscarnet therapy and subclinical HIV-1 involvement of the CNS may be factors responsible for seizure activity.

Download full-text PDF

Source
April 2016
9 Reads

Publication Analysis

Top Keywords

group identifiable
8
human immunodeficiency
8
seizures occurring
8
foscarnet therapy
8
involvement cns
8
hiv-1 involvement
8
control patients
8
patients
6
associated condition
4
epilepsy associated
4
including pre-hiv
4
lymphoma 14%
4
14% including
4
condition identified
4
pre-hiv epilepsy
4
42% patients
4
therapy time
4
time seizure
4
receiving foscarnet
4
18% receiving
4

Similar Publications